Evidence map›Paper›PMID 28450367›Full record

ReviewCirculation research2017

Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes.

Laila Staerk, Jason A Sherer, Darae Ko, Emelia J Benjamin, Robert H Helm

3 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 623 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
623citing papers in PubMed, 11 pooled it
37.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04038944 unknown statusnot on this mapstarted 2019, after this paper: background citation

Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring and Cardiac Imaging in Patients at Low Risk for Cardiovascular Events Following Direct Current Cardioversion for New Onset Atrial Fibrillation

TypeobservationalSponsorSt. Francis Hospital, New YorkRan2019 to 2023Enrolled250ConditionsNew Onset Atrial Fibrillation
NCT06202209 unknown statusnot on this mapstarted 2023, after this paper: background citation

The Impact of Autonomic Function on Recurrence Following Circumferential Pulmonary Vein Ablation for Atrial Fibrillation

TypeobservationalSponsorChina National Center for Cardiovascular DiseasesRan2023 to 2024Enrolled100ConditionsAtrial Fibrillation RecurrentArmsCircumferential Pulmonary Vein Isolation
NCT06417112 completednot on this mapstarted 2023, after this paper: background citation

Can Left Atrial Strain Measurements, and Correlating Changes in Left Atrium Area and Volume Size, be Used as an Early Predictor of Atrial Fibrillation?

TypeobservationalSponsorHywel Dda Health BoardRan2023 to 2024Enrolled72ConditionsAtrial Fibrillation, HypertensionArmsTransthoracic Echocardiogram
3 · Its place in the literature

Who cites it

623 citing papers in PubMed, 11 syntheses or guidelines pooled it, 1,197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Comparing simultaneous hybrid ablation with stand-alone thoracoscopic surgical ablation for the treatment of non-paroxysmal atrial fibrillation: a prospective randomized controlled trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Trial
  18. Article
  19. Sphingomyelin as a key negative mediator in atrial fibrillation via lipid profiling analysis and functional identification.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  20. Article

563 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Laila StaerkFrom the Cardiovascular Research Centre, Herlev and Gentofte University Hospital, Copenhagen, Denmark (L.S.); Department of Epidemiology, Boston University School of Public Health, MA (L.S., D.K., E.J.B.); Boston University and National Heart, Lung, and Blood Institute, Framingham Heart Study, MA (L.S., E.J.B.); and Department of Medicine (J.A.S.), Whitaker Cardiovascular Institute (D.K., E.J.B.), Section of Cardiovascular Medicine, Department of Medicine (D.K., E.J.B., R.H.H.), and Section of Preventive Medicine, Department of Medicine (E.J.B.), Boston University School of Medicine, MA. Lailastaerk@gmail.com Robert.Helm@bmc.org.
Jason A ShererFrom the Cardiovascular Research Centre, Herlev and Gentofte University Hospital, Copenhagen, Denmark (L.S.); Department of Epidemiology, Boston University School of Public Health, MA (L.S., D.K., E.J.B.); Boston University and National Heart, Lung, and Blood Institute, Framingham Heart Study, MA (L.S., E.J.B.); and Department of Medicine (J.A.S.), Whitaker Cardiovascular Institute (D.K., E.J.B.), Section of Cardiovascular Medicine, Department of Medicine (D.K., E.J.B., R.H.H.), and Section of Preventive Medicine, Department of Medicine (E.J.B.), Boston University School of Medicine, MA.
Darae KoFrom the Cardiovascular Research Centre, Herlev and Gentofte University Hospital, Copenhagen, Denmark (L.S.); Department of Epidemiology, Boston University School of Public Health, MA (L.S., D.K., E.J.B.); Boston University and National Heart, Lung, and Blood Institute, Framingham Heart Study, MA (L.S., E.J.B.); and Department of Medicine (J.A.S.), Whitaker Cardiovascular Institute (D.K., E.J.B.), Section of Cardiovascular Medicine, Department of Medicine (D.K., E.J.B., R.H.H.), and Section of Preventive Medicine, Department of Medicine (E.J.B.), Boston University School of Medicine, MA.
Emelia J BenjaminFrom the Cardiovascular Research Centre, Herlev and Gentofte University Hospital, Copenhagen, Denmark (L.S.); Department of Epidemiology, Boston University School of Public Health, MA (L.S., D.K., E.J.B.); Boston University and National Heart, Lung, and Blood Institute, Framingham Heart Study, MA (L.S., E.J.B.); and Department of Medicine (J.A.S.), Whitaker Cardiovascular Institute (D.K., E.J.B.), Section of Cardiovascular Medicine, Department of Medicine (D.K., E.J.B., R.H.H.), and Section of Preventive Medicine, Department of Medicine (E.J.B.), Boston University School of Medicine, MA.
Robert H HelmFrom the Cardiovascular Research Centre, Herlev and Gentofte University Hospital, Copenhagen, Denmark (L.S.); Department of Epidemiology, Boston University School of Public Health, MA (L.S., D.K., E.J.B.); Boston University and National Heart, Lung, and Blood Institute, Framingham Heart Study, MA (L.S., E.J.B.); and Department of Medicine (J.A.S.), Whitaker Cardiovascular Institute (D.K., E.J.B.), Section of Cardiovascular Medicine, Department of Medicine (D.K., E.J.B., R.H.H.), and Section of Preventive Medicine, Department of Medicine (E.J.B.), Boston University School of Medicine, MA.
Framingham Heart Study · USGentofte Hospital · DKNational Heart Lung and Blood Institute · US

Funding

IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6M
Research Training and Education Core (Core D) P50HL120163 · NHLBI · AMERICAN HEART ASSOCIATION · PI BHATNAGAR, ARUNI, ROBERTSON, ROSE MARIE · 2013 to 2017
$20.1M
AFGen Consortium: Atrial Fibrillation Genomics to Functional AnalysesR01HL128914 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2015 to 2018
$3.1M
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS N01 HC025195NHLBI NIH HHS P50 HL120163NHLBI NIH HHS R01 HL092577NHLBI NIH HHS R01 HL128914
6 · The paper itself

Abstract

The past 3 decades have been characterized by an exponential growth in knowledge and advances in the clinical treatment of atrial fibrillation (AF). It is now known that AF genesis requires a vulnerable atrial substrate and that the formation and composition of this substrate may vary depending on comorbid conditions, genetics, sex, and other factors. Population-based studies have identified numerous factors that modify the atrial substrate and increase AF susceptibility. To date, genetic studies have reported 17 independent signals for AF at 14 genomic regions. Studies have established that advanced age, male sex, and European ancestry are prominent AF risk factors. Other modifiable risk factors include sedentary lifestyle, smoking, obesity, diabetes mellitus, obstructive sleep apnea, and elevated blood pressure predispose to AF, and each factor has been shown to induce structural and electric remodeling of the atria. Both heart failure and myocardial infarction increase risk of AF and vice versa creating a feed-forward loop that increases mortality. Other cardiovascular outcomes attributed to AF, including stroke and thromboembolism, are well established, and epidemiology studies have championed therapeutics that mitigate these adverse outcomes. However, the role of anticoagulation for preventing dementia attributed to AF is less established. Our review is a comprehensive examination of the epidemiological data associating unmodifiable and modifiable risk factors for AF and of the pathophysiological evidence supporting the mechanistic link between each risk factor and AF genesis. Our review also critically examines the epidemiological data on clinical outcomes attributed to AF and summarizes current evidence linking each outcome with AF.

Indexed as

Atrial FunctionAction PotentialsAdultAgedAged, 80 and overAge FactorsAtrial FibrillationComorbidityFemaleGenetic Predisposition to DiseaseHeart Conduction SystemHeart RateHumansLife StyleMaleMiddle Agedatrial fibrillationepidemiologyprognosisrisk factorsstroke

Identifiers

PMID28450367
PMCPMC5500874
OpenAlexW2609696371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.